Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
Dow
Merck
Moodys

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Obatoclax

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Obatoclax?

Obatoclax is an investigational drug.

There have been 19 clinical trials for Obatoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Lung Neoplasms, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.

There are twenty-two US patents protecting this investigational drug and one hundred and ten international patents.

Recent Clinical Trials for Obatoclax
TitleSponsorPhase
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung CancerCephalonPhase 3
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1/Phase 2
Obatoclax for Systemic MastocytosisGemin XPhase 2

See all Obatoclax clinical trials

Clinical Trial Summary for Obatoclax

Top disease conditions for Obatoclax
Top clinical trial sponsors for Obatoclax

See all Obatoclax clinical trials

US Patents for Obatoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Obatoclax   Start Trial Mcl-1 antagonists The Regents of the University of California (Oakland, CA) The Royal Institute for the Advancement of Learning/McGill University (Montreal, CA)   Start Trial
Obatoclax   Start Trial Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
Obatoclax   Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Obatoclax   Start Trial Benzothiophene estrogen receptor modulators G1 Therapeutics, Inc. (Research Park Triangle, NC)   Start Trial
Obatoclax   Start Trial Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors GI Therapeutics, Inc. (Research Triangle Park, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Obatoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Obatoclax World Intellectual Property Organization (WIPO) 2015134539 2034-03-03   Start Trial
Obatoclax Australia 2016366680 2035-12-09   Start Trial
Obatoclax Brazil 112018011607 2035-12-09   Start Trial
Obatoclax Canada 3008020 2035-12-09   Start Trial
Obatoclax China 108495628 2035-12-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Colorcon
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.